Jurubidine | CAS#6084-44-2 | cyclised aglycone

MedKoo Cat#: 596335 | Name: Jurubidine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Jurubidine is a cyclised aglycone from Jurubine.

Chemical Structure

Jurubidine

CAS#6084-44-2

Theoretical Analysis

MedKoo Cat#: 596335

Name: Jurubidine

CAS#: 6084-44-2

Chemical Formula: C27H45NO2

Exact Mass: 415.3450

Molecular Weight: 415.66

Elemental Analysis: C, 78.02; H, 10.91; N, 3.37; O, 7.70

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Jurubidine;

IUPAC/Chemical Name

(2aS,4S,5'S,6aS,6bS,8aS,8bR,9S,10R,11aS,12aS,12bR)-5',6a,8a,9-tetramethyldocosahydrospiro[naphtho[2',1':4,5]indeno[2,1-b]furan-10,2'-pyran]-4-amine

InChi Key

BADUKLRFTFBRSD-PUHUBZITSA-N

InChi Code

InChI=1S/C27H45NO2/c1-16-7-12-27(29-15-16)17(2)24-23(30-27)14-22-20-6-5-18-13-19(28)8-10-25(18,3)21(20)9-11-26(22,24)4/h16-24H,5-15,28H2,1-4H3/t16-,17-,18-,19-,20+,21-,22-,23-,24-,25-,26-,27+/m0/s1

SMILES Code

[H][C@]1(O[C@@]2(OC[C@@H](C)CC2)[C@H]3C)C[C@@]4([H])[C@]5([H])CC[C@@]6([H])C[C@@H](N)CC[C@]6(C)[C@@]5([H])CC[C@]4(C)[C@]13[H]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 415.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Testi AM, Pession A, Diverio D, Grimwade D, Gibson B, de Azevedo AC, Moran L, Leverger G, Elitzur S, Hasle H, van der Werff Ten Bosch J, Smith O, De Rosa M, Piciocchi A, Lo Coco F, Foà R, Locatelli F, Kaspers GJL. Risk-adapted treatment of acute promyelocytic leukemia: results from International Consortium for Childhood APL. Blood. 2018 May 22. pii: blood-2018-03-836528. doi: 10.1182/blood-2018-03-836528. [Epub ahead of print] PubMed PMID: 29789356. 2: Correction: Daunorubicin reduces MBNL1 sequestration caused by CUG-repeat expansion and rescues cardiac dysfunctions in a Drosophila model of myotonic dystrophy (doi: 10.1242/dmm.032557). Dis Model Mech. 2018 May 18;11(5). pii: dmm035501. doi: 10.1242/dmm.035501. PubMed PMID: 29784710. 3: Karmo D, Hafeez A, Halalau A, Yadav S. Cardiac Tamponade as the Initial Presentation of Acute Myeloid Leukemia: A Case Report with Review of the Literature. Case Rep Oncol Med. 2018 Mar 26;2018:8201917. doi: 10.1155/2018/8201917. eCollection 2018. PubMed PMID: 29780652; PubMed Central PMCID: PMC5892271. 4: van Eijkelenburg NKA, Rasche M, Ghazaly E, Dworzak MN, Klingebiel T, Rossig C, Leverger G, Stary J, de Bont ESJM, Chitu DA, Bertrand Y, Brethon B, Strahm B, van der Sluis IM, Kaspers GJL, Reinhardt D, Zwaan CM. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study. Haematologica. 2018 May 17. pii: haematol.2017.187153. doi: 10.3324/haematol.2017.187153. [Epub ahead of print] PubMed PMID: 29773602. 5: Michel O, Kulbacka J, Saczko J, Mączyńska J, Błasiak P, Rossowska J, Rzechonek A. Electroporation with Cisplatin against Metastatic Pancreatic Cancer: In Vitro Study on Human Primary Cell Culture. Biomed Res Int. 2018 Mar 19;2018:7364539. doi: 10.1155/2018/7364539. eCollection 2018. PubMed PMID: 29750170; PubMed Central PMCID: PMC5884438. 6: Lian H, Meng Z. Melt electrospinning of daunorubicin hydrochloride-loaded poly (ε-caprolactone) fibrous membrane for tumor therapy. Bioact Mater. 2017 Apr 6;2(2):96-100. doi: 10.1016/j.bioactmat.2017.03.003. eCollection 2017 Jun. PubMed PMID: 29744416; PubMed Central PMCID: PMC5935042. 7: Lee SJ, Rho JY, Kim GI, Park J. Anterior mediastinal Hodgkin lymphoma presenting as an extremely hypervascular tumor on computed tomography: A case report. Medicine (Baltimore). 2018 May;97(19):e0607. doi: 10.1097/MD.0000000000010607. PubMed PMID: 29742695. 8: Balasubramanian P, Nampoothiri RV, Goni D, Malhotra P. Cutaneous herald: leukaemia cutis as presenting manifestation of relapse in acute promyelocytic leukaemia. BMJ Case Rep. 2018 May 2;2018. pii: bcr-2017-222906. doi: 10.1136/bcr-2017-222906. PubMed PMID: 29724869. 9: Schuster S, Biri-Kovács B, Szeder B, Farkas V, Buday L, Szabó Z, Halmos G, Mező G. Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin-GnRH-III conjugates developed for targeted drug delivery. Beilstein J Org Chem. 2018 Apr 4;14:756-771. doi: 10.3762/bjoc.14.64. eCollection 2018. PubMed PMID: 29719573; PubMed Central PMCID: PMC5905287. 10: Vinodhini MT, Sneha S, Nagare RP, Bindhya S, Shetty V, Manikandan D, Ganesan P, Sagar TG, Ganesan TS. Evaluation of a polymorphism in MYBPC3 in patients with anthracycline induced cardiotoxicity. Indian Heart J. 2018 Mar - Apr;70(2):319-322. doi: 10.1016/j.ihj.2017.07.001. Epub 2017 Jul 5. PubMed PMID: 29716714. 11: Lee JJ, Koh KN, Park CJ, Jang S, Im HJ, Kim N. The Combination of Flavokawain B and Daunorubicin Induces Apoptosis in Human Myeloid Leukemic Cells by Modifying NF-κB. Anticancer Res. 2018 May;38(5):2771-2778. PubMed PMID: 29715098. 12: Mizutani H, Nishimoto A, Hotta S, Ikemura K, Imai M, Miyazawa D, Ohta K, Ikeda Y, Maeda T, Yoshikawa M, Hiraku Y, Kawanishi S. Oxidative DNA Damage Induced by Pirarubicin, an Anthracycline Anticancer Agent, in the Presence of Copper(II). Anticancer Res. 2018 May;38(5):2643-2648. PubMed PMID: 29715084. 13: Chang VY, Wang JJ. Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity. Curr Oncol Rep. 2018 Apr 30;20(7):52. doi: 10.1007/s11912-018-0696-8. Review. PubMed PMID: 29713898. 14: Wang ES, O'Dwyer K. High dose daunorubicin: New standard of care for FLT3 ITD mutant AML. Leuk Res. 2018 Apr 23;69:87-88. doi: 10.1016/j.leukres.2018.04.011. [Epub ahead of print] PubMed PMID: 29705536. 15: Zhou J, Zhao Y, Gou Z. High 18F-fluorodeoxyglucose uptake in primary bilateral adrenal diffuse large B-cell lymphomas with nongerminal center B-cell phenotype: A case report. Medicine (Baltimore). 2018 Apr;97(17):e0480. doi: 10.1097/MD.0000000000010480. PubMed PMID: 29703006; PubMed Central PMCID: PMC5944495. 16: Franco MS, Oliveira MC. Liposomes co-encapsulating anticancer drugs in synergistic ratios as an approach to promote increased efficacy and greater safety. Anticancer Agents Med Chem. 2018 Apr 20. doi: 10.2174/1871520618666180420170124. [Epub ahead of print] PubMed PMID: 29692263. 17: Chen B, Lee JB, Kang H, Minden MD, Zhang L. Targeting chemotherapy-resistant leukemia by combining DNT cellular therapy with conventional chemotherapy. J Exp Clin Cancer Res. 2018 Apr 24;37(1):88. doi: 10.1186/s13046-018-0756-9. PubMed PMID: 29690909; PubMed Central PMCID: PMC5916833. 18: Sellar RS, Gale RE, Khwaja A, Garbowski M, Loddo M, Stoeber K, Williams GH, Linch DC. Immunophenotypic analysis of cell cycle status in acute myeloid leukaemia: relationship to cytogenetics, genotype and clinical outcome. Br J Haematol. 2018 Apr 20. doi: 10.1111/bjh.15211. [Epub ahead of print] PubMed PMID: 29676467. 19: Sorf A, Hofman J, Kučera R, Staud F, Ceckova M. Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro. Biochem Pharmacol. 2018 Apr 16;154:10-17. doi: 10.1016/j.bcp.2018.04.013. [Epub ahead of print] PubMed PMID: 29673999. 20: Mirzaei SA, Safari Kavishahi M, Keshavarz Z, Elahian F. Unlike Butylcycloheptylprodigiosin, Isolated Undecylprodigiosin from Streptomyces parvulus Is Not a MDR1 and BCRP Substrate in Multidrug-Resistant Cancers. DNA Cell Biol. 2018 Apr 19. doi: 10.1089/dna.2018.4161. [Epub ahead of print] PubMed PMID: 29672160.